Affimed (Nasdaq:AFMD) - Stock Price, News & Analysis

AFMD Stock Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe.

AFMD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 14.41% per year

Risk Analysis

Earnings are forecast to decline by an average of 1.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($71M)

Affimed N.V. Competitors

Genetron Holdings

NasdaqGM:GTH

US$74.3m

T2 Biosystems

NasdaqCM:TTOO

US$73.7m

G1 Therapeutics

NasdaqGS:GTHX

US$74.5m

Sorrento Therapeutics

OTCPK:SRNE.Q

US$51.1m

Price History & Performance

Summary of all time highs, changes and price drops for Affimed
Historical stock prices
Current Share Price	US$0.49
52 Week High	US$2.55
52 Week Low	US$0.45
Beta	2.11
1 Month Change	-8.98%
3 Month Change	-19.72%
1 Year Change	-77.12%
3 Year Change	-86.17%
5 Year Change	-89.42%
Change since IPO	-91.41%

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Recent updates

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Affimed N.V. initiates equity offering

Jan 12

Affimed inks €25M debt financing deal with Silicon Valley Bank

Jan 11

Affimed updates on product pipeline and cash balances

Jan 07

Affimed (NASDAQ:AFMD) Has Debt But No Earnings; Should You Worry?

Dec 25

What Did Affimed's (NASDAQ:AFMD) CEO Take Home Last Year?

Dec 04

Affimed teams up with Roivant Sciences in cancer

Nov 09

Shareholder Returns

	AFMD	US Biotechs	US Market
7D	3.6%	-1.4%	-1.1%
1Y	-77.1%	6.2%	14.1%

Return vs Industry: AFMD underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: AFMD underperformed the US Market which returned 17.5% over the past year.

Price Volatility

Is AFMD's price volatile compared to industry and market?
AFMD volatility
AFMD Average Weekly Movement	8.1%
Biotechs Industry Average Movement	9.1%
Market Average Movement	5.5%
10% most volatile stocks in US Market	14.1%
10% least volatile stocks in US Market	2.6%

Stable Share Price: AFMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AFMD's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	219	Adi Hoess	https://www.affimed.com

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.

Affimed N.V. Fundamentals Summary

How do Affimed's earnings and revenue compare to its market cap?
AFMD fundamental statistics
Market Cap	US$71.37m
Earnings (TTM)	-US$116.74m
Revenue (TTM)	US$35.73m

2.0x

P/S Ratio

-0.6x

P/E Ratio

Is AFMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AFMD income statement (TTM)
Revenue	€34.07m
Cost of Revenue	€25.95m
Gross Profit	€8.12m
Other Expenses	€119.43m
Earnings	-€111.31m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.75
Gross Margin	23.83%
Net Profit Margin	-326.75%
Debt/Equity Ratio	15.1%

How did AFMD perform over the long term?

See historical performance and comparison

AFMD Stock Overview

Rewards

Risk Analysis

Affimed N.V. Competitors

NasdaqGM:GTH

US$74.3m

NasdaqCM:TTOO

US$73.7m

NasdaqGS:GTHX

US$74.5m

OTCPK:SRNE.Q

US$51.1m

Price History & Performance

Recent News & Updates

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Recent updates

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)

Affimed: Preparing For A Bullish 2022

Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020)

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Consensus EPS estimates increase to -€0.25

Affimed: Current Fall And Future Prospects

First quarter 2021 earnings released: EPS €0.012 (vs €0.11 loss in 1Q 2020)